0 Replies
PASADENA, Calif. - October 27, 2011 - Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it has appointed Bruce Given, M.D. to the position of Chief Operating Officer of the Company effective October 26, 2011. Contine Reading & Discuss→
0 Replies
LAKE OSWEGO, Ore., Oct. 26, 2011 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biotechnology company focused on developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that data from the Phase 2 clinical trial of NeuVax™ will be presented at the 26th... Contine Reading & Discuss→
0 Replies
Stories include:
A new player in the nanoparticle drug-delivery game has arrived. Toronto-based DLVR Therapeutics raised seed funds from MaRS Innovation, bringing the upstart's total seed support to $2 million and fueling development of its nanoparticle programs for delivering chemo drugs and RNA-interference therapies, the company said.
The company was... Contine Reading & Discuss→
0 Replies
Stories include:
Arrowhead Research ($ARWR) has parachuted into the bombarded field of RNAi therapeutics armed with Swiss drug giant Roche's assets. As part of Pasadena, CA-based Arrowhead's acquisition of Roche's stake in the gene-silencing drugs, the firm picked up three drug-delivery technologies. The technologies include a delivery platform called "Dynamic... Contine Reading & Discuss→
0 Replies
Galena Biopharma submits SEC filing for spin-off of non-core RNAi assets.
Â
Galena will retain a 4% equity position, with the potential to receive up to $45 million in milestones; and 8% of the equity position in the RNAi company will be distributed to Galena shareholders after the filing is... Contine Reading & Discuss→
1 Reply
--Collaboration to investigate potential application of Silence’s novel AtuPLEX™ and DBTC delivery technologies in the development of novel microRNA therapeutics targeting cancer --
London, UK October XX, 2011 –Silence Therapeutics plc (AIM: SLN) (“Silence”), a leading RNA interference (RNAi) therapeutics company, today announced that it has entered into an agreement... Contine Reading & Discuss→
0 Replies
A research team led by scientists from The University of Texas MD Anderson Cancer Center have discovered four new "ZIP codes" in their quest to map the vast blood vessel network of the human body. Contine Reading & Discuss→
